

# Muhammad S Beg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4193597/publications.pdf>

Version: 2024-02-01

99  
papers

2,806  
citations

331670

21  
h-index

189892

50  
g-index

100  
all docs

100  
docs citations

100  
times ranked

5187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	2.6	647
2	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	1.6	350
3	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 325-334.	0.4	270
4	Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 874-881.	1.3	164
5	Surgical Outcome Results From SWOG S1505. <i>Annals of Surgery</i> , 2020, 272, 481-486.	4.2	155
6	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018, 37, 481-491.	1.4	88
7	The Future of Wearable Technologies and Remote Monitoring in Health Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 115-121.	3.8	79
8	Promise of Wearable Physical Activity Monitors in Oncology Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 82-89.	2.5	77
9	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	1.6	54
10	Liquid Biopsy for Cancer: Review and Implications for the Radiologist. <i>Radiology</i> , 2020, 294, 5-17.	7.3	52
11	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. <i>Cell Reports Medicine</i> , 2020, 1, 100034.	6.5	46
12	Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 102, 49-59.	2.0	45
13	Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 120.	2.8	38
14	NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 2601-2609.	7.0	37
15	Feasibility of Wearable Physical Activity Monitors in Patients With Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	2.1	36
16	Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 766-771.	1.3	32
17	Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 495-502.	1.4	32
18	A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 295-300.	4.4	31

#	ARTICLE	IF	CITATIONS
19	Approach and management of checkpoint inhibitor-related immune hepatitis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 220-224.	1.4	28
20	Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1312-1319.	3.4	27
21	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 83-88.	1.7	24
22	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With <i>Clostridium difficile</i> Infection: A Nationwide Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 466-472.	4.9	22
23	Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. <i>Clinical Endocrinology</i> , 2018, 88, 341-343.	2.4	22
24	Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. <i>Current Oncology Reports</i> , 2018, 20, 56.	4.0	21
25	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , 2019, 41, 1928-1934.	2.0	21
26	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	3.7	21
27	Telehealth and Palliative Care for Patients With Cancer: Implications of the COVID-19 Pandemic. <i>JMIR Cancer</i> , 2020, 6, e20288.	2.4	21
28	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. <i>Oncology</i> , 2020, 98, 179-185.	1.9	20
29	Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, e1327-e1332.	2.9	20
30	Time-Related Burdens of Cancer Care. <i>JCO Oncology Practice</i> , 2022, 18, 245-246.	2.9	19
31	Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 773-783.	0.8	18
32	Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	3.6	18
33	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	3.4	16
34	Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1904-1915.	4.1	15
35	Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage III Pancreatic Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1292-1300.	4.9	15
36	Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2018, 41, E11-E16.	2.0	13

#	ARTICLE	IF	CITATIONS
37	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 577-584.	2.3	12
38	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. <i>JAMA Oncology</i> , 2019, 5, e191973.	7.1	12
39	A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer. <i>JAMA Network Open</i> , 2022, 5, e2146912.	5.9	12
40	Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e98511.	2.5	11
41	Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study. <i>PLoS ONE</i> , 2016, 11, e0162845.	2.5	10
42	Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. <i>Cancers</i> , 2020, 12, 2501.	3.7	10
43	Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, 577-579.	2.9	10
44	Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis. <i>Oncology Nursing Forum</i> , 2017, 44, 165-170.	1.2	10
45	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 536-543.	3.0	9
46	Current status and future perspectives on the Internet of Things in oncology. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	9
47	Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. <i>Head and Neck</i> , 2017, 39, E69-E71.	2.0	8
48	Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes. <i>JCO Oncology Practice</i> , 2022, 18, e98-e107.	2.9	8
49	Improving the Time to Activation of New Clinical Trials at a National Cancer Institute-Designated Comprehensive Cancer Center. <i>JCO Oncology Practice</i> , 2020, 16, e324-e332.	2.9	7
50	A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 873-878.	4.9	7
51	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , 2021, 22, 455-464.	3.4	6
52	Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. <i>Pancreatology</i> , 2021, 21, 1009-1010.	1.1	6
53	Age-dependent prognostic value of <i>KRAS</i> mutation in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 4883-4893.	2.4	5
54	Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. <i>JMIR Cancer</i> , 2022, 8, e31388.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020, 15, 579-588.	3.6	4
56	Stage-specific Conditional Survival Among Young (Age Below 50%) Versus Older (Age 50% and Above) Adults With Colorectal Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 526-530.	1.3	4
57	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. <i>Cells</i> , 2021, 10, 1275.	4.1	4
58	GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4175-TPS4175.	1.6	4
59	Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14165-e14165.	1.6	4
60	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. <i>Gastrointestinal Tumors</i> , 2022, 9, 19-26.	0.7	4
61	Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016. <i>BMC Cancer</i> , 2018, 18, 1281.	2.6	3
62	Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. <i>Cancers</i> , 2020, 12, 2990.	3.7	3
63	Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 311-318.	1.3	3
64	Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net Hospital. <i>JCO Oncology Practice</i> , 2021, 17, e614-e622.	2.9	3
65	SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS547-TPS547.	1.6	3
66	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	1.4	2
67	The pattern of brain metastasis in colorectal cancer: Efficacy of metastasectomy, chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 40-40.	1.6	2
68	Implementation of a Quality Improvement Project to Increase Access to Dietitian Services for Patients With Gastrointestinal Cancer in a Safety-Net Hospital System. <i>JCO Oncology Practice</i> , 2021, 17, e1048-e1054.	2.9	2
69	Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.. <i>Journal of Clinical Oncology</i> , 2021, 39, 419-419.	1.6	2
70	Introduction of #PancChat: A novel Twitter platform to inform and engage the pancreatic cancer community.. <i>Journal of Clinical Oncology</i> , 2018, 36, 242-242.	1.6	2
71	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	2.9	1
72	The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 36-44.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Pathologic complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. Journal of Clinical Oncology, 2012, 30, 597-597.	1.6	1
74	Palliative care and end-of-life health utilization in elder patients with pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 488-488.	1.6	1
75	Can stereotactic ablative radiotherapy for oligometastatic pancreatic cancer help avoid perpetual chemotherapy and improve outcomes?. Journal of Clinical Oncology, 2022, 40, 571-571.	1.6	1
76	Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients.. Journal of Clinical Oncology, 2022, 40, 462-462.	1.6	1
77	Real-world treatment and outcomes of frontline chemotherapy in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16249-e16249.	1.6	0
78	Clinicopathologic variables and outcomes in elderly colorectal cancer patients with microsatellite instability and multiple primary malignancies.. Journal of Clinical Oncology, 2021, 39, e15516-e15516.	1.6	0
79	Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.. Journal of Clinical Oncology, 2021, 39, 3563-3563.	1.6	0
80	Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.. Journal of Clinical Oncology, 2021, 39, 4131-4131.	1.6	0
81	A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BILT-04).. Journal of Clinical Oncology, 2021, 39, TPS4158-TPS4158.	1.6	0
82	Sentiment analysis of tweets on prior authorization.. Journal of Clinical Oncology, 2021, 39, 322-322.	1.6	0
83	Impact of tumor location on effectiveness of first-line 5-FU-based palliative doublet chemotherapy in patients with metastatic gastroesophageal cancer.. Journal of Clinical Oncology, 2021, 39, 240-240.	1.6	0
84	Utilization of palliative care in intubated patients with metastatic cancer: A 10-year nationwide analysis.. Journal of Clinical Oncology, 2017, 35, 69-69.	1.6	0
85	Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2017, 35, 114-114.	1.6	0
86	Prescribing patterns for FOLFIRINOX in the real world.. Journal of Clinical Oncology, 2018, 36, 463-463.	1.6	0
87	Palliative care and end-of-life health care utilization of pancreatic cancer patients at an urban safety-net hospital.. Journal of Clinical Oncology, 2018, 36, 489-489.	1.6	0
88	Compliance with NCCN screening and chemoprevention recommendations among carriers of deleterious mutations in the adenomatous polyposis coli gene.. Journal of Clinical Oncology, 2018, 36, 571-571.	1.6	0
89	Effective use of electronic medical record (EMR) data in analysis of association between KRAS mutations and depression in colorectal cancer patients.. Journal of Clinical Oncology, 2018, 36, 861-861.	1.6	0
90	Association between environmental quality index and young onset colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 75-75.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Association between Environmental Quality Index and metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 521-521.	1.6	0
92	Patient-reported outcomes (PROs) in pancreatic cancer clinical trials (CTs).. Journal of Clinical Oncology, 2022, 40, 534-534.	1.6	0
93	Metastasectomy in colorectal cancer patients with concurrent lung and liver metastasis: Trends in utilization and impact on survival.. Journal of Clinical Oncology, 2022, 40, 53-53.	1.6	0
94	A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive).. Journal of Clinical Oncology, 2022, 40, TPS499-TPS499.	1.6	0
95	The role of serial analysis of hepatocellular carcinoma via circulating tumor DNA in identification of new actionable alterations.. Journal of Clinical Oncology, 2022, 40, 478-478.	1.6	0
96	Disparities in place of death (PoD) in patients with gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 645-645.	1.6	0
97	Characteristics and trends in treatment utilization in young-onset cholangiocarcinoma.. Journal of Clinical Oncology, 2022, 40, 386-386.	1.6	0
98	Cancer Commonsâ€™ virtual tumor board program: A patient-centric advisory panel and real-world data registry.. Journal of Clinical Oncology, 2022, 40, 527-527.	1.6	0
99	QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, QIM22-203.	4.9	0